JGUA
MRNA icon

John G. Ullman & Associates’s Moderna MRNA Stock Holding History

John G. Ullman & Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Buy
19,551
+1
+0% +$52 0.17% 95
2026
Q1 		$993K Sell
19,550
-1,600
-8% -$74.6K 0.13% 101
2025
Q4 		$624K Sell
21,150
-2,600
-11% -$70.6K 0.08% 120
2025
Q3 		$613K Buy
23,750
+7,650
+48% +$213K 0.08% 118
2025
Q2 		$444K Buy
16,100
+1,150
+8% +$30.3K 0.07% 127
2025
Q1 		$424K Buy
14,950
+4,650
+45% +$165K 0.07% 135
2024
Q4 		$428K Sell
10,300
-39,350
-79% -$1.88M 0.06% 134
2024
Q3 		$3.32M Buy
49,650
+38,400
+341% +$3.53M 0.48% 69
2024
Q2 		$1.34M Sell
11,250
-150
-1% -$19K 0.2% 94
2024
Q1 		$1.21M Buy
11,400
+7,750
+212% +$781K 0.19% 91
2023
Q4 		$363K Sell
3,650
-37,949
-91% -$3.19M 0.06% 135
2023
Q3 		$4.3M Buy
41,599
+13,200
+46% +$1.47M 0.7% 43
2023
Q2 		$3.45M Buy
+28,399
New +$3.79M 0.53% 54

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

John G. Ullman & Associates's MRNA Position: Q2 2026 in Review

John G. Ullman & Associates increased its Moderna (MRNA) stake by 0.01% in Q2 2026, buying an estimated $52 and bringing the position to 19,551 shares worth $1.37M. The position accounts for 0.17% of the portfolio, ranked #95.

John G. Ullman & Associates first reported a position in MRNA in Q2 2023 and has held it in 13 quarters since. The position peaked at $4.3M in Q3 2023. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • John G. Ullman & Associates held 19,551 shares of Moderna worth $1.37M as of Q2 2026.
  • John G. Ullman & Associates bought 1 Moderna share in Q2 2026, an estimated $52.
  • Moderna made up 0.17% of John G. Ullman & Associates's portfolio in Q2 2026, its #95 holding.
  • John G. Ullman & Associates first reported a position in Moderna in Q2 2023 and has held it in 13 quarters since.
  • John G. Ullman & Associates's Moderna position peaked at $4.3M in Q3 2023.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on John G. Ullman & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.